Movatterモバイル変換

[0]ホーム
URL:

Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Oncogene
  • Original Paper
  • Published:

UCS15A, a novel small molecule, SH3 domain-mediated protein–protein interaction blocking drug

Oncogenevolume 21, pages2037–2050 (2002)Cite this article

Abstract

Protein–protein interactions play critical regulatory roles in mediating signal transduction. Previous studies have identified an unconventional, small-molecule, Src signal transduction inhibitor, UCS15A. UCS15A differed from conventional Src-inhibitors in that it did not alter the levels or the tyrosine kinase activity of Src. Our studies suggested that UCS15A exerted its Src-inhibitory effects by a novel mechanism that involved the disruption of protein–protein interactions mediated by Src. In the present study we have examined the ability of UCS15A to disrupt the interaction of Src–SH3 with Sam68, bothin vivo andin vitro. This ability of UCS15A was not restricted to Src–SH3 mediated protein–protein interactions, since the drug was capable of disrupting thein vivo interactions of Sam68 with other SH3 domain containing proteins such as Grb2 and PLCγ. In addition, UCS15A was capable of disrupting other typical SH3-mediated protein–protein interactions such as Grb2–Sos1, cortactin–ZO1, as well as atypical SH3-mediated protein–protein interactions such as Grb2–Gab1. However, UCS15A was unable to disrupt the non-SH3-mediated protein–protein interactions of β-catenin, with E-cadherin and α-catenin. In addition, UCS15A had no effect on the SH2-mediated interaction between Grb2 and activated Epidermal Growth Factor receptor. Thus, the ability of UCS15A, to disrupt protein–protein interactions appeared to be restricted to SH3-mediated protein–protein interactions. In this regard, UCS15A represents the first example of a non-peptide, small molecule agent capable of disrupting SH3-mediated protein–protein interactions.In vitro analyses suggested that UCS15A did not bind to the SH3 domain itself but rather may interact directly with the target proline-rich domains.

This is a preview of subscription content,access via your institution

Access options

Access through your institution

Subscribe to this journal

Receive 50 print issues and online access

￥40,000 per year

only ￥800 per issue

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

￥ 4,980

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Andreotti AH, Bunnell SC, Feng S, Berg LJ, Schreiber SL . 1997Nature385: 93–97

  • Bar-Sagi D, Rotin D, Batzer A, Mandiyan V, Schlessinger J . 1993Cell74: 83–91

  • Birge R, Knudsen B, Besser D, Hanafusa H . 1996Genes to Cells1: 595–613

  • Cicchetti P, Mayer B, Thiel G, Baltimore D . 1992Science257: 803–806

  • Cohen GB, Ren R, Baltimore D . 1995Cell80: 237–248

  • Combs A, Kapoor T, Feng S, Chen J, Daude-Snow L, Schreiber S . 1996J. Am. Chem. Soc.118: 287–288

  • Dalgarno D, Botfield M, Rickles R . 1997Biopoly.43: 383–400

  • Feng S, Kasahara C, Rickles R, Schreiber S . 1995Proc. Natl. Acad. Sci.92: 12408–12415

  • Finan P, Hall A, Kellie S . 1996FEBS. L.389: 141–144

  • Franz WM, Berger P, Wang JY . 1989EMBO J.8: 137–147

  • Fumagalli S, Totty N, Hsuan J, Courtneidge S . 1994Nature368: 871–874

  • Fusaki N, Iwanatsu A, Iwashima M, Fujisawa J . 1997J. Biol. Chem.272: 6214–6219

  • Gale N, Kaplan S, Lowenstein E, Schlessinger J, Sagi D . 1993Nature363: 88–90

  • Gorina S, Pavletich NP . 1996Science274: 1001–1005

  • Hanke JH, Gardner JP, Dow RL, Changelian PS, Brisette WH, Weringer EJ, Pollok BA, Connelley PA . 1996J. Biol. Chem.271: 695–701

  • Huber A, Weis W . 2001Cell105: 391–402

  • Hulsken J, Birchmeier W, Behrens J . 1994J. Cell Biol.127: 2061–2069

  • Hunter T . 2000Cell100: 113–127

  • Jabado N, Jauliac S, Pallier A, Bernard F, Fischer A, Hivroz X . 1998J. Immunol.161: 2798–2803

  • Jackson P, Baltimore D . 1989EMBO J.8: 449–456

  • Ji X, Zhang P, Armstrong RN, Gilliland GL . 1992Biochem.31: 10169–10184

  • Kato M, Miyazawa K, Kitamura N . 2000J. Biol. Chem.275: 37481–37487

  • Katsube T, Takahisa M, Hashimoto N, Kobayashi M, Togashi S . 1998J. Biol. Chem.273: 29672–29677

  • Kay BK, Williamson MP, Sudol M . 2000FASEB J.14: 231–241

  • Koch C, Anderson D, Moran M, Ellis C, Pawson T . 1991Science252: 668–674

  • Ladbury J, Arold S . 2000Chem. Biol.7: R3–R8

  • Lewitzky M, Kardinal C, Gehring NH, Schmidt EK, Konkol B, Eulitz M, Birchmeier W, Schaeper U, Feller SM . 2001Oncogene20: 1052–1062

  • Li N, Batzer A, Daly R, Yajnik V, Skolnik E, Chardin P, Sagi D, Margolis B, Schlessinger J . 1993Nature363: 85–88

  • Lowenstein E, Daly R, Batzer A, Li W, Margolis B, Lammers R, Ullirich A, Schlessinger J . 1992Cell70: 431–442

  • Mano H . 1999Cytokine Growth Factor Rev.10: 267–280

  • Manser E, Loo TH, Koh CG, Zhao ZS, Chen XQ, Tan L, Tan I, Leung T, Lim L . 1998Mol. Cell1: 183–192

  • Mayer B, Baltimore D . 1993Trends Cell Biol.3: 8–13

  • Mayer BJ . 2001J. Cell. Sci.114: 1253–1263

  • Mayer BJ, Baltimore D . 1994Mol. Cell Biol.14: 2883–2894

  • Mongiovi AM, Romano PR, Panni S, Mendoza M, Wong WT, Musacchio A, Cesareni G, Paolo Di Fiore P . 1999EMBO J.18: 5300–5309

  • Nguyen J, Porter M, Amoui M, Miller W, Zuckermann R, Lim W . 2000Chem. Biol.7: 463–473

  • Nguyen JT, Lim WA . 1997Nature4: 256–260

  • Nishida M, Nagata K, Hachimori Y, Horiuchi M, Ogura K, Mandiyan V, Schlessinger J, Inagaki F . 2001EMBO J.20: 2995–3007

  • Pai L, Kirkpatrick C, Blanton J, Oda H, Takeichi M, Peifer M . 1996J. Biol. Chem.271: 32411–32420

  • Parker MW, Bello ML, Federici G . 1990J. Mol. Biol.213: 221–222

  • Pawson T . 1995Nature373: 573–580

  • Pawson T, Schlessinger J . 1993Curr. Biol.3: 434–442

  • Pillay I, Nakano H, Sharma SV . 1996Cell Growth Differ.7: 1487–1499

  • Ponting CP, Aravind L, Schultz J, Bork P, Koonin EV . 1999J. Mol. Biol.289: 729–745

  • Reinemer P, Dirr HW, Ladenstein R, Schaffer J, Gallay O, Huber R . 1991EMBO J.10: 1997–2005

  • Ren R, Mayer BJ, Cicchetti P, Baltimore D . 1993Science259: 1157–1161

  • Richard S, Yu DY, Blumer KJ, Hausladen D, Olszowy MW, Connelly PA, Shaw AS . 1995Mol. Cell. Biol.15: 186–197

  • Rickles RJ, Zoller MJ . 1994EMBO J.13: 5598–5604

  • Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D . 1993Nature363: 83–85

  • Rubin GM, Yandell MD, Wortman JR, Gabor Miklos GL, Nelson CR, Hariharan IK, Fortini ME, Li PW, Apweiler R, Fleischmann W, Cherry JM, Henikoff S, Skupski MP, Misra S, Ashburner M, Birney E, Boguski MS, Brody T, Brokstein P, Celniker SE, Chervitz SA, Coates D, Cravchik A, Gabrielian A, Galle RF, Gelbart WM, George RA, Goldstein LS, Gong F, Guan P, Harris NL, Hay BA, Hoskins RA, Li J, Li Z, Hynes RO, Jones SJ, Kuehl PM, Lemaitre B, Littleton JT, Morrison DK, Mungall C, O'Farrell PH, Pickeral OK, Shue C, Vosshall LB, Zhang J, Zhao Q, Zheng XH, Lewis S . 2000Science287: 2204–2215

  • Schaeper U, Gehring NH, Fuchs KP, Sachs M, Kempkes B, Birchmeier W . 2000J. Cell Biol.149: 1419–1432

  • Schlessinger J . 1994Curr. Opin. Genet. Dev.4: 25–30

  • Schwartzberg PL . 1998Oncogene17: 1463–1468

  • Seidel-Dugan C, Meyer BE, Thomas SM, Brugge JS . 1992Mol. Cell. Biol.12: 1835–1845

  • Sharma SV, Oneyama C, Yamashita Y, Nakano H, Sugawara K, Hamada M, Kosaka N, Tamaoki T . 2001Oncogene20: 2068–2079

  • Shen Z, Batzer A, Koehler JA, Polakis PP, Schlessinger J, Lydon NB, Moran MF . 1999Oncogene18: 4647–4653

  • Smithgall T . 1995J. Pharmacol Toxicol Methods34: 125–132

  • Sparks A, Quilliam L, Thorn J, Der C, Kay B . 1994J. Biol. Chem.269: 23853–23856

  • Sparks AB, Rider JE, Hoffman NG, Fowlkes DM, Quilliam LA, Kay BK . 1996Proc. Natl. Acad. Sci. USA93: 1540–1544

  • Sudol M . 1998Oncogene17: 1469–1474

  • Summy J, Guappone A, Sudol M, Flynn D . 2000Oncogene19: 155–160

  • Taylor S, Anafi M, Pawson T, Shalloway D . 1995J. Biol. Chem.270: 10120–10124

  • Taylor SJ, Shalloway D . 1994Nature368: 867–871

  • Tsukita S, Furuse M, Itoh M . 1999Curr. Opin. Cell Biol.11: 628–633

  • Yamashita Y, Miyazato A, Ohya K, Ikeda U, Shimada K, Miura Y, Ozawa K, Mano H . 1996Jpn. J. Cancer Res.87: 1106–1110

  • Yu H, Chen J, Feng S, Dalgarno D, Brauer A, Schreiber S . 1994Cell76: 933–945

  • Zhu T, Goh ELK, LeRoith D, Lobie PE . 1998J. Biol. Chem.273: 33864–33875

Download references

Acknowledgements

We thank Dr Margaret Quinlan for carefully editing the manuscript and for her valuable comments.

Author information

Authors and Affiliations

  1. Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd 3-6-6 Asahi-cho, Machida-shi, Tokyo, 194, Japan

    Chitose Oneyama, Hirofumi Nakano & Sreenath V Sharma

Authors
  1. Chitose Oneyama
  2. Hirofumi Nakano
  3. Sreenath V Sharma

Corresponding author

Correspondence toSreenath V Sharma.

Rights and permissions

About this article

Cite this article

Oneyama, C., Nakano, H. & Sharma, S. UCS15A, a novel small molecule, SH3 domain-mediated protein–protein interaction blocking drug.Oncogene21, 2037–2050 (2002). https://doi.org/10.1038/sj.onc.1205271

Download citation

Keywords

This article is cited by

Access through your institution
Buy or subscribe

Advertisement

Search

Advanced search

Quick links

[8]ページ先頭
©2009-2026 Movatter.jp